Findings

What do systematic reviews say?

2,061 questions · 2,151 findings · 116 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 609 · 28.3%GRADE not reported 268 · 12.5%Very low 635 · 29.5%Low 491 · 22.8%Moderate 122 · 5.7%High 26 · 1.2%

Analgesic (any: NSAID, paracetamol, local anaesthetic or opioid) vs placebo or control

Time off school or work · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for pain relief during orthodontic treatment 2017 · Cochrane All outcomes
No studies in this comparison reported this outcome.
0 studies
No studies found

Pilocarpine vs no treatment/placebo

Other oral related symptoms (oral discomfort, eating difficulty, mucosal pain, oral complications) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT
Insufficient evidence of a difference: oral discomfort MD -18.00 (95% CI -37.41 to 1.41); eating difficulties MD -14.40 (95% CI -35.38 to 6.58); mucosal pain MD -14.80 (95% CI -37.07 to 7.47); oral complications RR…
2 studies
GRADE not reported

Amifostine (intravenous) vs Amifostine (subcutaneous)

Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No data on either quality of life or other oral related symptoms were reported.
0 studies
No studies found

Bethanechol vs Artificial saliva

Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Bethanechol led to higher salivary flow rate (stimulated, ml/min) compared with artificial saliva; GRADE not reported.

2 findings from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
8 to 40 weeks postRT
MD 0.21 [0.01, 0.41]
1 study · 29 participants
GRADE not reported
Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT
MD 0.13 [-0.03, 0.29]
1 study · 32 participants
GRADE not reported

Topical NSAID (ketoprofen lysinate mouthwash, 160 mg) vs Topical NSAID (benzidamine hydrochloride mouthwash, 22.5 mg)

Adverse events · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for pain relief during orthodontic treatment 2017 · Cochrane All outcomes
The study did not report this outcome.
0 studies
No studies found

Bethanechol vs placebo

Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No statistical difference between groups in bethanechol-related toxicity; no patient experienced severe (grade 3) toxicity (Jaguar 2015)
1 study
GRADE not reported

Amifostine (intravenous) vs Amifostine (subcutaneous)

Xerostomia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine (intravenous) led to lower xerostomia (grade >= 2, 0-4 scale) compared with amifostine (subcutaneous); GRADE not reported.

2 findings from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
12 months postRT
RR 0.61 [0.42, 0.88]
1 study · 127 participants
GRADE not reported
Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Up to and including 3 months postRT
RR 1.03 [0.76, 1.40]
1 study · 263 participants
GRADE not reported

Antiseptic mouthrinse vs placebo

Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No relevant adverse events were reported in any group (Lanzos 2010)
1 study
GRADE not reported

Bethanechol vs placebo

Xerostomia (grade >= 2, 0-3 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Bethanechol led to lower xerostomia (grade >= 2, 0-3 scale) compared with placebo; GRADE not reported.

2 findings from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT
RR 0.43 [0.28, 0.66]
1 study · 84 participants
GRADE not reported
Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Up to and including 3 months postRT
RR 0.81 [0.65, 1.01]
1 study · 84 participants
GRADE not reported

Bethanechol vs placebo

Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Bethanechol showed no clear difference in salivary flow rate (stimulated, ml/min) compared with placebo; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
2 months postRT
MD 0.15 [-0.03, 0.33]
1 study · 97 participants
GRADE not reported

Pilocarpine vs no treatment/placebo

Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Any time point
No evidence of a difference between treatment groups for stimulated salivary flow at any time point (Analysis 1.5)
8 studies
GRADE not reported

Amifostine vs no treatment/placebo

Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

It is very uncertain whether amifostine changes overall survival compared with no treatment/placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
12 to 24 months postRT
HR 1.18 [0.85, 1.66]
2 studies · 271 participants
Very low

Bethanechol vs placebo

Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Bethanechol led to higher salivary flow rate (unstimulated, ml/min) compared with placebo; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
2 months postRT
MD 0.19 [0.06, 0.32]
1 study · 97 participants
GRADE not reported

Antimicrobial lozenge vs placebo

Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No survival data were reported.
0 studies
No studies found

Venalot Depot (coumarin plus troxerutin) vs placebo

Survival (locoregional control) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Unable to use the data on locoregional control (Grotz 2001)
1 study
GRADE not reported

Analgesic (any: NSAID, paracetamol, local anaesthetic or opioid) vs placebo or control

Adverse events · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for pain relief during orthodontic treatment 2017 · Cochrane All outcomes
No studies in this comparison reported any adverse events. SoF cell: 'Not reported'.
0 studies
No studies found

Vaginal PGE₂ vs placebo or expectant management

Vaginal delivery not achieved within 24 hours · patients with induction of labour at term

1 finding from 1 review

Pharmacological and mechanical interventions for labour induction in outpatient settings 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Intracervical PGE₂ vs placebo

Uterine hyperstimulation with fetal heart rate changes · women requiring induction of labour

Intracervical PGE₂ showed no clear difference in uterine hyperstimulation (with fetal heart rate changes) compared with placebo (low certainty).

1 finding from 1 review

Pharmacological and mechanical interventions for labour induction in outpatient settings 2017 · Cochrane Headline outcomes only
RR 2.66 [0.63, 11.25]
4 studies · 488 participants
Low

Intracervical PGE₂ vs placebo

Caesarean section · women requiring induction of labour

Intracervical PGE₂ showed no clear difference in caesarean section compared with placebo (moderate certainty).

1 finding from 1 review

Pharmacological and mechanical interventions for labour induction in outpatient settings 2017 · Cochrane Headline outcomes only
RR 0.9 [0.72, 1.12]
7 studies · 674 participants
Moderate

Intracervical PGE₂ vs placebo

Neonatal death or serious neonatal perinatal morbidity · women requiring induction of labour

1 finding from 1 review

Pharmacological and mechanical interventions for labour induction in outpatient settings 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported